Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-CIK Treatment in Hepatocellular Carcinoma
NCT01821482Phase 2Unknown
- Sponsor
- Guangxi Medical University
- Start
- May 2013
- Primary completion
- May 2018
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of dendritic cell vaccine + cytokine-induced killer cells in hepatocellular carcinoma (HCC), sponsored by Guangxi Medical University. Status: unknown.
02
Drugs
dendritic cell vaccine + cytokine-induced killer cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01821482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01821482.